Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar User Fee Negotiations Won't Start Until 2016

Executive Summary

Mid-December kick-off meeting puts emerging user fee program on much later track than others.

You may also be interested in...

Biosimilar User Fee Talks Reach Starting Line As Report Shows Growing FDA Workload

Agency staff efforts dedicated to 351(k) reviews increased more than 10-fold in fiscal year 2015, Eastern Research Group says.

Biosimilar Market Formation Isn't Going According To Plan

As user fee negotiations begin, FDA has far more sponsors in product development phase and far fewer marketing applications than anticipated.

Biosimilar User Fees Could Be Raised Significantly In Renewal Talks

Workload is not what was expected when BsUFA was designed, FDA says.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts